DE60142899D1 - Verbindungen für den transfer von oligonukleotiden - Google Patents

Verbindungen für den transfer von oligonukleotiden

Info

Publication number
DE60142899D1
DE60142899D1 DE60142899T DE60142899T DE60142899D1 DE 60142899 D1 DE60142899 D1 DE 60142899D1 DE 60142899 T DE60142899 T DE 60142899T DE 60142899 T DE60142899 T DE 60142899T DE 60142899 D1 DE60142899 D1 DE 60142899D1
Authority
DE
Germany
Prior art keywords
oligonucleotides
compounds
transfer
collagen
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142899T
Other languages
English (en)
Inventor
Shunichiro Kubota
Masaaki Terada
Takahiro Ochiya
Hiroshi Itoh
Masayasu Furuse
Akihiko Sano
Shunji Nagahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
National Cancer Center Japan
Sumitomo Pharma Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Dainippon Pharma Co Ltd
National Cancer Center Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Dainippon Pharma Co Ltd, National Cancer Center Japan filed Critical Koken Co Ltd
Application granted granted Critical
Publication of DE60142899D1 publication Critical patent/DE60142899D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
DE60142899T 2000-06-20 2001-06-19 Verbindungen für den transfer von oligonukleotiden Expired - Lifetime DE60142899D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000184502 2000-06-20
PCT/JP2001/005195 WO2001097857A1 (fr) 2000-06-20 2001-06-19 Preparations destinees au transfert d'oligonucleotides

Publications (1)

Publication Number Publication Date
DE60142899D1 true DE60142899D1 (de) 2010-10-07

Family

ID=18684937

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142899T Expired - Lifetime DE60142899D1 (de) 2000-06-20 2001-06-19 Verbindungen für den transfer von oligonukleotiden

Country Status (10)

Country Link
US (3) US20040052840A1 (de)
EP (1) EP1295611B1 (de)
JP (1) JP5118285B2 (de)
AT (1) ATE478688T1 (de)
AU (1) AU2001264317A1 (de)
DE (1) DE60142899D1 (de)
DK (1) DK1295611T3 (de)
ES (1) ES2349137T3 (de)
PT (1) PT1295611E (de)
WO (1) WO2001097857A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
ATE478688T1 (de) * 2000-06-20 2010-09-15 Dainippon Sumitomo Pharma Co Verbindungen für den transfer von oligonukleotiden
DK1407787T3 (da) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
EP1550463A4 (de) * 2002-09-20 2006-12-27 Dainippon Sumitomo Pharma Co Vorbereitungsweg zur erleichterung der situsspezifischen genumwandlung und vorbereitungsweg für die gentherapie
EP1696034A4 (de) * 2003-12-19 2006-12-27 Dainippon Sumitomo Pharma Co Neues verfahren zum nukleinsäuretransfer
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) * 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
ES2405357T3 (es) * 2005-05-25 2013-05-30 Cellmid Limited Composición farmacéutica para la vasculopatía oclusiva.
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
FR3066115B1 (fr) * 2017-05-10 2019-06-28 Universite de Bordeaux Comprimes de vecteurs d'acides nucleiques

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (de) * 1972-11-01 1976-05-14
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (fr) * 1992-08-20 1994-11-10 Coletica Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
JPH08510742A (ja) * 1993-05-28 1996-11-12 カイロン コーポレイション ウロキナーゼレセプター活性のペプチドインヒビター
US6068857A (en) * 1993-09-09 2000-05-30 Schering Aktiengesellchaft Microparticles containing active ingredients, agents containing these microparticles, their use for ultrasound-controlled release of active ingredients, as well as a process for their production
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
EP0769063A1 (de) * 1994-06-27 1997-04-23 The Johns Hopkins University Gezielte freigabe genetischen materials
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
CN1230205C (zh) * 1995-07-03 2005-12-07 株式会社高研 基因制剂
JP3867160B2 (ja) * 1995-07-03 2007-01-10 大日本住友製薬株式会社 遺伝子製剤
EP0859636A4 (de) * 1995-10-23 2002-05-02 Hyal Pharmaceutical Australia Hyaluronsäure als dna träger für die gentherapie sowie vegf antisense-dna zur behandlung abnormaler netzhautvaskularisierung
WO1997022371A1 (en) * 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
EP0904373A1 (de) * 1996-03-14 1999-03-31 The Immune Response Corporation Zielgerichtete abgage von interferon-kodierenden genen
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) * 1996-10-31 1999-02-23 Matrix Pharmaceutical, Inc. Aseptic collagen concentration process
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) * 1996-12-23 2001-04-17 Cobra Therapeutics Limited Optimization of gene delivery and gene delivery system
EP2319854B1 (de) * 1997-01-08 2016-11-30 Sigma-Aldrich Co. LLC Biokonjugation von Makromolekülen
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
AU2868099A (en) * 1998-02-13 1999-08-30 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
AU755126B2 (en) * 1998-05-22 2002-12-05 Dainippon Sumitomo Pharma Co., Ltd. Stable gene preparations
EP2363133A1 (de) * 2000-03-31 2011-09-07 Trustees of Boston University Zusammensetzung enhalted DNA-Fragmente und ihre medizinischen und kosmetischen Verwendungen
ATE478688T1 (de) * 2000-06-20 2010-09-15 Dainippon Sumitomo Pharma Co Verbindungen für den transfer von oligonukleotiden
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
DK1407787T3 (da) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004022075A1 (en) * 2002-09-04 2004-03-18 Novartis Ag Treatment of neurological disorders by dsrna adminitration
EP1550463A4 (de) * 2002-09-20 2006-12-27 Dainippon Sumitomo Pharma Co Vorbereitungsweg zur erleichterung der situsspezifischen genumwandlung und vorbereitungsweg für die gentherapie
WO2004042024A2 (en) * 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
DE602004028587D1 (de) * 2003-01-16 2010-09-23 Univ Pennsylvania ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
US8227434B1 (en) * 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
EP1720893B1 (de) * 2004-02-26 2014-08-13 Baylor Research Institute Zusammensetzungen und verfahren zur systemischen behandlung von arthritis
CN102643818B (zh) * 2004-09-28 2014-04-09 夸克制药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
CN101060863B (zh) * 2004-10-22 2012-06-06 拉瓦勒大学 疼痛的治疗和预防中神经胶质细胞来源的bdnf的调节
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2007082899A1 (en) * 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2007144985A1 (ja) * 2006-06-16 2007-12-21 Taisho Pharmaceutical Co., Ltd. Ｒｐｎ２遺伝子発現抑制剤の用途
RU2553561C2 (ru) * 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Средства ингибирования экспрессии протеинкиназы 3
WO2008028085A2 (en) * 2006-08-30 2008-03-06 The Board Of Trustees Of The University Of Illinois Modulation of mlck-l expression and uses thereof
US7902167B2 (en) * 2006-10-02 2011-03-08 Aprea Ab Compounds and methods for down-regulating Wrap53 protein by RNA interference
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
WO2011069155A1 (en) * 2009-12-04 2011-06-09 Opko Ophthalmics, Llc Compositions and methods for inhibition of vegf

Also Published As

Publication number Publication date
EP1295611A4 (de) 2009-07-08
AU2001264317A1 (en) 2002-01-02
ATE478688T1 (de) 2010-09-15
JP5118285B2 (ja) 2013-01-16
EP1295611B1 (de) 2010-08-25
US20110028535A1 (en) 2011-02-03
EP1295611A1 (de) 2003-03-26
PT1295611E (pt) 2010-09-14
WO2001097857A1 (fr) 2001-12-27
DK1295611T3 (da) 2010-10-04
US20090258933A1 (en) 2009-10-15
US20040052840A1 (en) 2004-03-18
ES2349137T3 (es) 2010-12-28

Similar Documents

Publication Publication Date Title
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
TW200502385A (en) Modulation of forkhead box o1a expression
EP1190099A4 (de) Antisense-modulierung der p13k p85 expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
WO2001029175A3 (en) Antisense modulation of fra-1 expression
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE50009838D1 (de) Humanes antibiotisches protein
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1359943T3 (da) Biotinderivater og deres konjugater med chelateringsmidler
PT1165444E (pt) Utilizacao de derivados de porfirina em aquarios
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2003033659A3 (en) Antisense modulation of matrix metalloproteinase 1 expression
WO2002040637A3 (en) Antisense modulation of pi3k p85 expression
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
WO2004052301A3 (en) Modulation of matrix metalloproteinase 11 expression
WO2004052306A3 (en) Modulation of ppar-alpha expression
WO2003106646A3 (en) ANTISENSE MODULATION OF DOUBLE SPECIFIC PHOSPHATASE 4 EXPRESSION
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
UA38418A (uk) Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози
WO2002044325A3 (en) Antisense modulation of src-1 expression
ITBO990456A0 (it) Metodo per il trattamento del terreno .
UA34350A (uk) Спосіб комплексного лікування генералізованого пародонтиту